Proc. NatI. Acad. Sci. USA
Vol. 86, pp. 3559-3563, 1989
Biochemistry


Peptide sequencing site-directed mutagenesis identify
tyrosine-727 active site tyrosine Saccharomyces
cerevisiae DNA topoisomerase      (vaccinia virus topoisomerase/camptothecin/phosphotyrosine/enzyme-DNA trans-esterification)
RICHARD M. LYNN, MARY-ANN BJORNSTI*, PAUL R. CARON, JAMES C. WANG
Department Biochemistry Molecular Biology, Harvard University, Cambridge, MA 02138
Contributed James C. Wang, February 1, 1989

ABSTRACT          Extensive digestion covalent interme-               resealing step reactions normally catalyzed topo-
diate DNA Saccharomyces cerevisiae DNA topo-                     isomerases. formation drug-topoisomerase-DNA
isomerase trypsin yields 7-amino acid peptide cova-                 ternary complex, inactivation enzyme
lently linked DNA. Direct sequencing DNA-linked                    subsequent disruption essential cellular process, peptide identifies Tyr-727 active site tyrosine forms            responsible cell killing drugs ofthis class (11-15). 04-phosphotyrosine bond DNA enzyme                          case DNA topoisomerase specific drug camptothe-
cleaves DNA phosphodiester bond. Site-directed mutagenesis                 cin, shown yeast cells killed drug cloned yeast  gene encoding enzyme confirms                   gene  encoding DNA topoisomerase  essentiality Tyr-727 relaxation supercoiled                nonessential enzyme yeast, expressed; mutant cells
DNA enzyme. amino acid sequence homology,                        devoid enzyme resistant drug (24, 27).
Tyr-771 -773 readily identified active site                   Clearly, killing yeast TOP1+ cells camptothecin tyrosines Schizosaceharomyces pombe human DNA                         inactivation enzyme consequence
topoisomerase  respectively. Sequence comparison site-                 formation cytotoxic drug-topoisomerase-DNA
directed mutagenesis implicate Tyr-274 vaccinia virus                ternary complex.
DNA topoisomerase active site residue. appears                 understand catalysis DNA strand breakage 70-amino acid domain near carboxyl terminus                      rejoining topoisomerases certain drugs
eukaryotic DNA topoisomerase vaccinia topoisomerase,                   interfere trans-esterification reactions, active site tyrosine resides.                               undertaken mapping active site tyrosines                                                                              prokaryotic eukaryotic topoisomerases.  participation DNA topoisomerases number                   cently reported results active sites Escherichia
vital processes, including replication, transcription, genetic               coli DNA gyrase (DNA topoisomerase II), yeast DNA
recombination, chromosomal decondensation,                       topoisomerase II (25, 26). communication, report
documented  recent reviews, refs. 1-3; refs.                identification Tyr-727 active site tyrosine 4-8). enzymes catalyze transient breakage DNA                   Saccharomyces cerevisiae DNA topoisomerase  sep-
strands form enzyme-mediated gates                       arate communication published  intact DNA strand pair DNA strands double helix                 Tyr-319 E. coli DNA topoisomerase active site pass. distinct types DNA topo-                          tyrosine (R.M.L. J.C.W., unpublished data).  isomerases organisms examined date: type                       active sites DNA breakage rejoining repre-
enzyme forms gate strands                   sentative type type II prokaryotic eukaryotic DNA
duplex DNA, type II enzyme forms                         topoisomerases determined. sequence com-
double-stranded gate duplex DNA transiently cleaving                   parisons, active sites similar enzymes orga- paired strands concert (refs. 1-3; refs.             nisms, ranging viruses human, deduced.
9 10).
   DNA topoisomerase transiently breaks DNA
backbone bond, simultaneously forms protein-DNA link,                                MATERIALS METHODS tyrosyl oxygen enzyme joined DNA                     Materials, Bacterial Strains, Plasmids. E. coli K-12
phosphorus end enzyme-severed DNA strand                       strain NK7048 [(Alac pro)xiii ara nalA argEam thi rifR F'
(1-3). Reversal cleavage reaction restores DNA                    laclq'] collection N. Kleckner (Harvard
backbone bond frees enzyme additional reaction                   University); strain TG1 supplied Amersham. pBlue-
cycles (1-3).                                                                script KS(+) purchased Stratagene. lactone
   past decade, number therapeutically important                 form drug camptothecin purchased Sigma.
antibiotics antitumor agents target                  Yeast DNA topoisomerase purified E. coli
DNA topoisomerases (reviewed refs. 11-15). large                        NK7048 cells harboring ptacTOP1, multicopy plasmid fraction drugs characterized trapping               coding sequences yeast topoisomerase class complexes DNA DNA topo-                               expressed trp-lac hybrid promoter Ptac (28). Expres-
isomerases termed "cleavable complexes." com-                      sion yeast enzyme induced addition plexes named cleavage DNA backbone                     isopropyl /3-D-thiogalactoside (IPTG) 1 mM. Cells bonds, simultaneous formation DNA-enzyme                          harvested 3 hr induction lysed lysozyme-Brij
links, revealed exposure protein denaturants                58 method. Polymin P precipitation, (NH4)2S04 precipitation
(16-23). likely drugs interfere DNA
                                                                             Abbreviation: IPTG, isopropyl B-D-thiogalactoside. publication costs article defrayed page charge   *Present address: Department Biochemistry Molecular Biol-
payment. article marked "advertisement"         ogy, Institute Molecular Medicine, Jefferson Medical College, accordance 18 U.S.C. §1734 solely indicate fact.              Thomas Jefferson University, Philadelphia, PA 10917.
 3560     Biochemistry: Lynn et al.                                              Proc. Natl. Acad. Sci. USA 86 (1989) proteins Polymin P supernatant phosphocellu-        phenol/chloroform/isoamyl alcohol mixture (50:49:1,
lose chromatography according ref. 29,        vol/vol). aqueous phase assay mixed (NH4)2SO4 cuts 40 o 80  saturation.         loading buffer containing Ficoll tracking dyes addition, buffers used purification procedure      loaded sample 1.1  agarose slab. Electropho- described ref. 27. Pooled fractions phos-       resis 0.1 M Tris borate buffer 2 V/cm.
phocellulose step chromatographed heparin-
agarose described (29) purification yeast DNA                                  RESULTS
topoisomerase II. Approximately 1.8 mg yeast DNA
topoisomerase purity >90  obtained 6           Direct Sequencing DNA-Linked Tryptic Peptide S.
liters E. coli culture.                                        cerevismae  DNA Topoisomerase Identifies Tyr-727    Preparation Yeast DNA Topoisomerase Derived           Active Site Tyrosine. unambiguous way identifying Tryptic Peptide Covalently Linked DNA. 2.2-ml mixture        active site topoisomerase breakage rejoining
containing 2.1 mg yeast DNA topoisomerase  300 pug        substrate form covalent enzyme-DNA com-
EcoRI linearized pHC624, derivative pBR322, 10 mM            plex, digest complex endopeptidase, se-
Tris HC1, pH 8.0/5 mM Na3EDTA/120 mM KCI/450 uM                   quence DNA-linked peptide. peptide sequence
camptothecin incubated 30'C 10 min. SDS            directly reveals position DNA-linked amino acid added 1  form covalent complex yeast            topoisomerase polypeptide chain (25-27). method
DNA topoisomerase DNA, sample pre-              requires isolation sufficient DNA-
cipitated sodium acetate ethanol.                        linked peptide amino acid sequencing. case yeast
   Treatment alcohol-precipitated covalent complex         DNA topoisomerase  preparation relatively large trypsin, purification DNA-linked tryptic peptide,     DNA-linked peptide facilitated  amino acid sequencing DNA-linked peptide          production enzyme E. coli (28) enhancement
carried according described procedures (25-27);       covalent complex formation enzyme recovery starting DNA -80 . William S. Lane        DNA presence drug camptothecin (20). Harvard Microchemical Facility performed peptide          Fig. 1 illustrates formation covalent complex
sequencing; assignment phenylthiohydantoin deriva-         yeast DNA topoisomerase linear double-
tives information peptide          stranded DNA  Materials Methods details). sequenced source protein.                            formation protein-DNA covalent link accom-
   Site-Directed Mutagenesis. 326-base-pair (bp) Spe Pst      panied breakage DNA backbone bond, extent
 DNA fragment containing active site tyrosine codon      covalent complex formation estimated yeast  gene obtained ptacTOP1          number scissions DNA strand. shown lane 4, cloned polylinker region plasmid pBluescript          mixture containing 2.1 mg yeast DNA topoisomerase  KS(+). slightly larger Xba Pst DNA fragment contain-       (=20 nmol) 300 Ag linear pHC624 DNA (0.5 nmol  ing entire 326 bp original TOP1 fragment  inserted Xba Pst sites polylinker                                  1 2 3 4
 region double-stranded replicative form phage
 M13mpl9 DNA. ligated DNA transformed E.
 coli strain TG1 individual white phage plaques  indicator plates containing 5-bromo-4-chloro-3-indolyl 03-
 D-galactopyranoside IPTG purified, checked  presence correct insert, used make single-
 stranded DNA site-directed mutagenesis.
    Specific amino acid substitutions yeast enzyme  accomplished oligonucleotide-directed method  Nakamaye Eckstein (30), using kit supplied Amer-
 sham. oligonucleotides synthesized changing Tyr-727
 phenylalanine serine, Asn-726 leucine, Ile-725
 Asn-726 arginine alanine  respectively,
5'-AATCAATTTTATAGACCC-3', 5'-AATCAATTCTAT-
AGACCC-3', 5'-CCAAAATCCT'TTATATAGACCC-3', 5'-CCAAAATACCT'T'ATATAGACCC-3'. Single-stranded
DNA samples prepared purified phage plaques, presence desired base pair changes determined nucleotide sequencing using kit supplied United States
Biochemical.
  double-stranded replicative form phage DNA prepared, Spe Pst DNA restriction fragment               FIG. 1.   Cleavage linearized pHC624 (2014 bp) yeast    DNA
containing mutagenized region excised used          topoisomerase 20-,ul
                                                                                        reaction  mixture containing 3 tg pHC624
replace wild-type DNA fragment ptacTOP1.                    DNA, 18 ,ug topoisomerase  10 mM Tris-HCl, pH 8.0/120 mM
  Activity Assays. IPTG added final concentration      KCI/5 mM EDTA/450 mM camptothecin/5               (vol/vol) dimethyl
1 mM 6-ml cultures optical densities 595 nm       sulfoxide incubated 300C 10 min. 2 ml 10  SDS 0.3-0.5 induce expression yeast DNA topo-           added obtain covalent complex. sample digested
isomerase  Cells harvested 2.5 hr induction,      proteinase K, phenol extracted, alcohol precipitated redis-
                                                                   solved, denatured alkaline, loaded lane 4 ofwere      1 
extracts prepared described (28), 30 ,ul    alkaline-agarose gel. Samples loaded lanesDNA         2 M KCI added prior centrifugation extract.          follows: lane 1, HindIll restriction fragments phage        used
  relaxation negatively supercoiled DNA yeast            size markers; lane 2, linear pHC624 DNA; lane 3, DNA topoisomerase vitro assayed described (31).        loaded lane 4 DNA topoisomerase omitted Endogenous E. coli DNA topoisomerase activity            incubation. Electrophoresis 1 V/cm 18 hr; gel detectable assays. reaction terminated          stained ethidium neutralization,   photographed
extracting mixture equal volume                   UV illumination.
          Biochemistry: Lynn et al.                                                 Proc. Natl. Acad. Sci. USA 86 (1989)            3561

strands), bulk 2-kilobase-pair DNA contains                         1    2    3    4     5    6 scission strand. densitometric           tracing negative gel photograph showed afew percent DNA strands remained intact, strand scissions average;  nanomole amounts complex formed. Untreated DNA (lane 2), DNA
mock-treated omission topoisomerase initial reaction (lane 3), contained intact strands.
   Treatment covalent complex trypsin sequencing DNA-linked peptide carried summarized Materials Methods described (25-27). amino acids cycles Edman degradation isoleucine asparagine. assignable amino acid peaks cycle. cycles contained isoleucine, aspartic acid,
proline, arginine, "blank," respectively. se-
quence compared published sequence yeast
enzyme (32), readily concluded observed peptide
sequencing pattern corresponds exactly expected peptide Ile -Asn-Tyr727                           Tyr-727 point covalent attachment DNA  gave           FIG. 2. Relaxation supercoiled DNA wild-type mutant assignable peaks Edman cycle).              yeast DNA topoisomerase  Extracts IPTG-induced E. coli cells
sequences protein match 50o 7-amino         prepared relaxation 0.3 kug negatively supercoiled
acid stretch. Furthermore, amino acid 724 yeast topoiso-          pHC624 DNA yeast DNA topoisomerase extract merase lysine trypsin expected cleave         assayed described. Extracts obtained cells expressing position, Arg-731, 7-amino   mutant yeast DNA topoisomerase following substitutions:
acid peptide linked DNA.                                          lane 1, Tyr-727 phenylalanine; lane 2, Tyr-727 serine; lane 3,
   Site-Directed Mutagenesis Yeast  Gene Confirms         Asn-726 leucine; lane 4, Ile-725 Asn-726 arginine                                                                      alanine, respectively. Lane 5 contained DNA treated extract
Essentiality Tyr-727 Catalysis. Mutating Tyr-727     cells expressing wild-type yeast DNA topoisomerase  lane
phenylalanine serine (described Materials Methods)         6 contained untreated pHC624 DNA.
inactivates yeast DNA topoisomerase  shown Fig. 2
(lanes 1 2). Extracts E. coli cells expressing            consensus sequence surrounding active site tyrosines
wild-type yeast enzyme relaxed supercoiled DNA fully             eukaryotic type enzymes Leu-Gly-Thr-
(lane 5), 1/100th extract used assay         Ser-Lys-Ile-Asn-Tyr (active site), 5 7 amino acids
 shown. experiments, absence activity         immediately preceding putative active site tyrosines mutant cell extracts proteolysis yeast          dissimilar. amino acids eukaryotic 
enzymes. Immunostaining yeast DNA topoisomerase                 sensus essential activity,  Directly specific antibodies showed extracts cells express-      preceding active site tyrosine, example, aspar-
 ing wild-type mutant proteins contained compara-         agine. asparagine mutated leucine ble amounts intact yeast DNA topoisomerase (data            S. cerevisiae enzyme, resulting mutant enzyme remained
shown).                                                              fully active, shown lane 3 Fig. 2.
  Comparison Amino Acid Sequences Type DNA                 low degree homology exhibited amino
Topoisomerases Yeasts, Human, Vaccinia Virus                acids surrounding Tyr-274 vaccinia enzyme Identifies Active Site Tyrosines Enzymes.           surrounding active site tyrosines type relatively high degree homology exhibited known            topoisomerases significant. test possibility,
amino acid sequences S. cerevisiae, S. pombe,             Ile-725 Asn-726 S. cerevisiae DNA topoisomer-
human DNA topoisomerase (32-34) makes straightfor-              ase mutated arginine alanine ward deduce Tyr-771 S. pombe enzyme               corresponding positions vaccinia topoisomerase. Tyr-723 human enzyme homologous Tyr-727             mutated enzyme fully active (Fig. 2, lane 4).  S. cerevisiae enzyme active site           sequence yeast enzyme match tyrosines enzymes.                                          environment presumed active site tyrosine vaccinia
  type topoisomerase particular           topoisomerase, activity retained. results support encapsidated vaccinia virus particles (35).            assignment residue 274 active site tyrosine enzyme unusual size         vaccinia topoisomerase based homology search.
typical eukaryotic type DNA topoisomerase resistant drug camptothecin (36, 37, 41). vaccinia enzyme
shows considerable amino acid sequence homology yeast                                      DISCUSSION human DNA topoisomerase  published                  direct sequencing DNA-linked tryptic peptide sequence comparison (36, 38) homologous regions           S. cerevisiae DNA topoisomerase  coupled site-
include residues corresponding active site tyrosines       directed mutagenesis data described Results, clearly iden- eukaryotic topoisomerases described                        tify Tyr-727 active site tyrosine S. cerevisiae
   30-amino acid region surrounding              enzyme. Sequence comparisons mutagenesis data active site tyrosines human yeast enzymes          permit assignment active site tyrosines used sequence similarity search using PROFILE          eukaryotic type topoisomerases known sequences program (39), low degree homology identifiable              strongly implicate Tyr-274 vaccinia virus-encoded highly conserved yeast human sequences               enzyme active site residue. vaccinia virus; Tyr-224 vaccinia enzyme              Fig. 3 depicts comparison amino acid sequences appeared correspond Tyr-727 budding yeast           DNA topoisomerase S. cerevisiae, S. pombe, human,
Discussion). residues surrounding Tyr-274 viral          vaccinia virus DNA topoisomerase. active site
enzyme Pro-Ser-Ile-Lys-Arg-Asn-Tyr274 compared              tyrosine region -70 amino acids shares
 3562        Biochemistry: Lynn et al.                                                                                                                   Proc. Natl. Acad. Sci. USA 86              (1989)
       Sp                                                                                                  MS SS DS VS LS[ jE1R RQ RR GS S                             Kr1 ISM[R1E          D . 30
        H MSGDHLHNDSQ                                  EADFRLNDSHKHKDKHKDREHSHKEHKKEKDKS[EK                                                                                    SOHL           N St 53

       Sc                        MT ArA SFV NHELSSDDDDDVPLSQTL R KIV S 34
       Sp ES[SSEN1PLS SL     K S K[SEED P KRRASSKKNMSN SSKK RAKV M 82
        H HKID SEK  E
                   KEK DJKTKHD G SI   KHKIDHK D DKEKRK E EKVR G     E K 106

       Sc M[iSAILQDEAEPYDS
                        K E1 ED1NE AI
       Sp GINGGLKNGKKTAVVK
                          D  E S KI S]KPTI
                                             S
                                                jEPVQSS[                        87
                                                JHIKR1VSKANG[KNGJAIK1SAVKKEE SD 135
                                                                                                                                                                  LPSPKAIK~ISATSE]P
        H ENGFFPSPPQ KDEPE   GCY YPP     D PL[KJPRDEDDADYKJK ErE D TEK 159

       Sc KE]IK2EDGDnKV2TTf   EE   N    KREEEEEED        Sp TDDSVPL RAVSTVS L rPYKS EL PSGAS T TONRSPNDE E
                                                                                                                                                           EE E E     K
                                                                                                                                                            ED Y K WwSE
                                                                                                                                                                        E   140
                                                                                                                                                                         ID 188
       H    E~gK L E E E E D GEJL KIK P K N K D K D VPEPD N K K KEP                                                                                  KK EE E   KWW ERY P 212

               W VP
               TPY
            Sc[0~~~~~~_F      N GH             IH      dK        KPVDL                                                 L Y Y D G                          PP OA EE VA GF F                    193

       Sp [1KWT
          D T      TLLEH±NGVIFAPPYEPLPIKINVKKL AYDGLJNIL                                                                                                    PPEAEEVAiGFrAA ML                       241
        G KWK   E                      KM YY DG  K                                                                                                       KAEEV                                 265


          S|DHAKN                      VfQK                                                                                                 El KEF SRCDFTKMD                         LQLK E         246
       Sc
       Sp TDHAK NPVFQDNF
                                   P               N   F       F       NL
                                                               FRDFLKVICDL
                                                                       V                                   FF
                                                                                                           CN
                                                                                                               S
                                                                                                                     jHtN.
                                                                                                                   GGPLnG                 . .IIKEFSKCDFT MFH                     F E QK R E         291
             INFFK SWR
       HHEYTTKE                    KM                                    MI                                 E E             .       .   .    .          M       AEPT             K      E         314

       ScQVDYKFUEL
            1SrQ E     R      F            JE                                                                                                           G N F KvF-          299
       SpEK[ PIKEJKAK EKK D E E KY    LDGRKEK                                                                                                           GNF  EPPGLFRGRGSH 344
       H                           ASK
                                    K                                       F
                                      L LKE
                                      L       Q FNR- R                                                                                                      NGRG N            367
       V                                                                                                                                                      M R AL FYDI K L 11

       SclP   K TG|KLKRR                     NPED0 V iLISKK 0 P V               RH TV     M REN                                                                                              352
       Sp IPK
       H
                   TGISLKROR
                      MLKRR
                                            |YIPEOIE                                              MPE DI
                                                        Ni G              G
                                                                    PEPLPGH W AE V HDNTVTWLATIWIHIENII
                                                       K DAKVPStPPGHKWKEVRH D Nn TWL SWTENI
                                                                                                                                                                                                    397
                                                                                                                                                                                                    420
       V FTDNN                             PSDDNPAYEVLQHJ1JTHlJT D V V VVYLEO0rw E E AL      FVGSDS                                                                                               64

       Sc FmN   F     R     NSSLKGQSDYKKFEKAROLISY IDAI R D RN K KVL R 405
       Sp NNN[VIK YVFLA GSS LK GOS DILKKYEK JRK |LKIDYI DDI R[ G IYRKD.L KIN EL T V RI 450
        H OIG 3I K YMLYVMN SSIRJIKK
                                  EKRWL
                                    W        KRRKKcV        RNROYREDWK SKEKVR 473
        V K fRRFYGKMHVHONRNARDR            RVYNVMKR NC         KN K     K*T D S N      115

       Sc          W               YD                                      AE-                              * | ADTVGCCSLRYEHVTLKPPN . .                                                     T V 451
       Sp    R     AMY L DVFALRAGNEKGIEDE- ADTVGCCSLRYEHVT'LKPPR.T.V                                                                                                                              496
        H IQ R ANV         IALRAGN EEn1ETA DVGCCSL                          NI1HPELDGQEYVrY                                                                                                         525
        V            M TM F KI       F          g
                                             Y L KL-        SGL
                                                           VE.        K E              E                                                                                    .   .   .         160
       SciJFDFYLGVKVDVS      R       T  EfQVFKNTPFKRPPKQ PHOLFDRR LDPS                  KYL                                                                                                       504
                                                                     DLFO R L sfNSLN K Y Ll
       SPlIV F D F L G K D S IkRYY NE V E V D QV FK N LIK F KR PP KK LP                                                                                                                             549
        H EIF Lf   L G K D S R YLY       FVNVF  K N LG               EE Q  D   RLLGNHL|                                                                                                           577
        V VI K FVVq                         s           LT        PE FI           RKVYEC                                                                                                         212
       SCN MPG L TrA K V FMR       T Y N ASK TM          556
                                                      DL mN KG .S VAECK L K
       Sp SLA      DGLQAKVFRTYNASYTMA               L DK 601      TLIAIK ILIFIYNRANRVA LC
                                                            KNL * T
        H [MD L M EIGAKVFRTYNAS t1TL LKELTAPOENIA      630                 LSY NRANRAI2IJLC
        VKOF.                                  K.238
                                                N YNFWTN 28                                                                       .           ..   .   ..     .     ..     .




       SC NHQRT VTKGrHIAQTVKA N NROCL EEWK RCKRA LDKDKDLIKEPKYFEE 609
       Sp NHQRSIVTKNWjDVQOMERFAERIKALOYIRMRLRKMMUJNJEPKLJAISKPELLAKE 654 652
       H |N H RJAPP1idTF EKSMMNLQ TKjD...                                                                           .........                          .............




       ScDDLTKEDEAT KR I DR [ YQR[KF 1VREN1DIRKFE- ELWLPES1QEKEW1E 661
       SpEGITDSWIVKHHETLYELL K IEKK1KFDIRENERKLAAUPKSMLPESE        EVR K 707
        H      ..............               . . ..
                                                . . .
                                                   ........    K  EQ   668
                                                                          RRDLKSA      .



        V                  y- -..............................................
       SC
       Sp D
                                0 EFEELKTGEP1ELKSSWNS WNSVKIKA QLE
                                Q
                                   ADLDAL
                               KALAEK     KISKKSO P G RSS M EOEK
                                                              L
                                                                                        KE E714
                                                                   RLN1KL JEERINVMRTIQOMMIDLEI 758                                                      LEQRIQTSSIQ7L
        HK                        DA
                                M K...K..V V        -.     .V S KKKAJ0R]LEE LMKLEVQAJITILEI 710
                                                                           .   .   .



        V..    .   .   .   .   .   .   .   .   .           .       .   .   .   .   .   .       261
                                                                                               .   .   .   .   .     .
                                                                                                                         ..   .       .JS SPPSPKKLIALTIlTAL
      SC RSIV SIL GTSK N Y D PW_         R L|EV| KY|D V P E K F L K FIKWA                                R             6
      SP  KTTLGT         sNY II NY II DPRLTYSL K E DVPIEK1nLS K T RDKFNIWAWDITPPDWKW                            V                812
       HSINHK11ALGISK
                  ~IA  LGT          DPRlmLtSVVKKYDlVP.
                                    YL             AW       K          E K         KT       C FAWLMfD YE176
                                                                                                     F      DM          YE        765
       V VVGHPT                 RAlMA ..TLf L E                 .KNF L              K TIFDCLS VVDHVKSSTDG 314
  FIG. 3. Alignment predicted protein sequences eukaryotic vaccinia virus DNA topoisomerase  S. cerevisiae (Sc) S. pombe
(Sp) sequences aligned using PROFILE program (39). Homology putative domains -30 amino acids long optimized.        human sequence (H) aligned, followed alignment vaccinia virus sequence (V) sequences. Residues identical boxed. Gaps inserted sequences indicated dots. active site tyrosine S. cerevisiae enzyme predicted
active sites enzymes marked asterisk. Amino acids designated single-letter code. homology proteins. residues, including                                                                             large gap (-160 amino acids long) 70-amino active site tyrosine, conserved corresponding                                                                                  acid carboxyl-terminal region region upstream positions region.                                                                                                                 strong homology polypeptides   shown Fig. 3, vaccinia enzyme sequence                                                                                suggests 70-amino acid carboxyl-
          Biochemistry: Lynn et al.                                                    Proc. Natl. Acad. Sci. USA 86 (1989)            3563

terminal region forms distinct domain yeast            6. Zhang, H., Wang, J. C. & Liu, L. F. (1988) Proc. Natl. Acad. human type topoisomerases domain separated                     Sci. USA 85, 1060-1064. domain "linker" peptides =160 amino acids                 7. Christman, M. F., Dietrich, F. S. & Fink, G. R. (1988) Cell 55,
                                                                             413